Safety and Clinical Activity of the Programmed Death-Ligand 1 Inhibitor Durvalumab in Combination With Poly (ADP-Ribose) Polymerase Inhibitor Olaparib or Vascular Endothelial Growth Factor Receptor 1-3 Inhibitor Cediranib in Women's Cancers: A Dose-Escalation, Phase I Study

Lee, Jung-Min ; Cimino-Mathews, Ashley ; Peer, Cody J ; Zimmer, Alexandra ; Lipkowitz, Stanley ; Annunziata, Christina M ; Cao, Liang ; Harrell, Maria I ; Swisher, Elizabeth M ; Houston, Nicole ; Botesteanu, Dana-Adriana ; Taube, Janis M ; Thompson, Elizabeth ; Ogurtsova, Aleksandra ; Xu, Haiying ; Nguyen, Jeffers ; Ho, Tony W ; Figg, William D ; Kohn, Elise C

Journal of clinical oncology, 2017-07, Vol.35 (19), p.2193-2202 [Periódico revisado por pares]

United States: American Society of Clinical Oncology

Texto completo disponível